Assessing Delayed Treatment Benefits of Immunotherapy Using Long-Term Average Hazard: A Novel Test/Estimation Approach
用长期平均风险评估免疫治疗的延迟获益AI 解读 ↓
← 返回论文列表与筛选
阅读说明
本页整理公开书目信息，不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成，未完成全文核验，可能有误；具体假设、证明与结论请核对原文。摘要保留来源文本，未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要；缺少可靠材料时保留待补状态。
本页为预印本版本；arXiv 收录、作者填写的期刊信息以及作者既有发表经历，都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对，只展示已核实例，档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录，不合计多个记录；关联记录可能包含正式发表版本，不等于此版本单独引用。缺失不视为零，引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配，同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列，再参考通用方法与发表日期。
分类依据与纠错
AI 根据所提供的论文材料归类：摘要明确针对随机对照研究中的治疗效应检验与效应大小估计，给定分类中最直接对应因果推断。
反馈分类问题
正在核对关联版本…
代码、数据与补充材料
正在核对对应版本的资源…
用长期平均风险评估免疫治疗的延迟获益
- 研究问题
- 当免疫治疗的生存获益延迟出现时，如何同时获得有解释意义的效应度量与有效组间检验，是本文研究的核心问题。
- 方法与思路
- 作者结合长期限制平均生存时间与生存加权平均风险的思路，提出长期平均风险指标，并以其差值和比值进行效应估计与检验。
- 材料陈述的贡献
- 摘要称，该方法保持检验与估计的一致性，效应度量不依赖研究特定的删失时间分布，并在部分数值场景中获得更高检验功效。
- 阅读关注点
- 应核对长期窗口如何选取、删失处理与推断条件、差值及比值的临床解释，并查看功效提升出现的场景和其他场景的表现。
- 阅读边界
- 这是 arXiv 预印本，同行评审或期刊接收未获核实；摘要未说明删失假设或具体数值结果，部分场景的功效优势不能推广至所有情形。
原文摘要
Delayed treatment effects on time-to-event outcomes have often been observed in randomized controlled studies of cancer immunotherapies. In the case of delayed onset of treatment effect, the conventional test/estimation approach using the log-rank test for between-group comparison and Cox's hazard ratio to estimate the magnitude of treatment effect is not optimal, because the log-rank test is not the most powerful option, and the interpretation of the resulting hazard ratio is not obvious. Recently, alternative test/estimation approaches were proposed to address both the power issue and the interpretation problems of the conventional approach. One is a test/estimation approach based on long-term restricted mean survival time, and the other approach is based on average hazard with survival weight. This paper integrates these two ideas and proposes a novel test/estimation approach based on long-term average hazard (LT-AH) with survival weight. Numerical studies reveal specific scenarios where the proposed LT-AH method provides a higher power than the two alternative approaches. The proposed approach has test/estimation coherency and can provide robust estimates of the magnitude of treatment effect not dependent on study-specific censoring time distribution. Also, the proposed LT-AH approach can summarize the magnitude of the treatment effect in both absolute difference and relative terms using ``hazard'' (i.e., difference in LT-AH and ratio of LT-AH), meeting guideline recommendations and practical needs. This proposed approach can be a useful alternative to the traditional hazard-based test/estimation approach when delayed onset of survival benefit is expected.